BofA raised the firm’s price target on Denali Therapeutics (DNLI) to $31 from $29 and keeps a Buy rating on the shares after the company announced the accelerated approval of Avlayah for the treatment of Hunter syndrome. The firm, which models $525M in potential peak sales for Avlayah, calls this “a pivotal moment” as Denali transitions to becoming a commercial organization.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target raised to $41 from $34 at Stifel
- Denali Therapeutics price target raised to $32 from $29 at Baird
- Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
- Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
- Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy